Diabetic dyslipidemia: evaluation and mechanism

被引：23

作者：

Yanai, Hidekatsu ^{[1
]}

Hirowatari, Yuji ^{[2
]}

Yoshida, Hiroshi ^{[3
]}

机构：

[1] Kohnodai Hosp, Dept Internal Med, Natl Ctr Global Hlth & Med, 1-7-1 Kohnodai, Chiba 2720034, Japan

[2] Saitama Prefectural Univ, Sch Hlth & Social Serv, Dept Hlth Sci, Lab Sci, Saitama, Japan

[3] Jikei Univ, Dept Lab Med, Kashiwa Hosp, Chiba, Japan

来源：

GLOBAL HEALTH & MEDICINE | 2019年 / 1卷 / 01期

关键词：

Diabetes; high-performance liquid chromatography; insulin resistance; lipoproteins; triglyceride;

D O I：

10.35772/ghm.2019.01007

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Diabetes is one of the well-established independent risk factors for cardiovascular diseases. Diabetes induces dyslipidemia which is characterized by elevated fasting triglyceride (TG) and reduced high-density lipoprotein-cholesterol (HDL-C), and such diabetic dyslipidemia is a crucial determinant for atherogenesis and atherosclerotic progression in patients with diabetes. Previous measurement methods of lipoproteins have problems including time-consuming (ultracentrifugation) and inaccurate and impossible measurements of TG-rich lipoproteins such as chylomicron, intermediate-density lipoprotein (IDL) and very low-density lipoprotein (VLDL). Our developed anion-exchange high-performance liquid chromatography (AEX-HPLC) can measure all fractions of lipoproteins accurately. Our studies using AEX-HPLC showed that IDL and VLDL in type 2 diabetes were higher than non-diabetic subjects, and IDL and VLDL were higher in the order of type 2 diabetic patients with obesity, type 2 diabetic patients without obesity, and non-diabetic subjects. Here, we also describe the underlying mechanisms for development of diabetic dyslipidemia.

引用

页码：30 / 35

页数：6

共 42 条

[1] Ballantyne CM, 1998, AM J CARDIOL, V82, p3Q
[2] Caslake M.J., 1997, HDB LIPOPROTEIN TEST, P509
[3] The degradation of apolipoprotein B100: Multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways
Fisher, Edward A.
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2012, 1821 (05): : 778 - 781
[4] INTERNATIONAL CLASSIFICATION OF HYPERLIPIDEMIAS AND HYPERLIPOPROTEINEMIAS
FREDRICKSON, DS
[J]. ANNALS OF INTERNAL MEDICINE, 1971, 75 (03) : 471 - +
[5] FRINGS CS, 1971, CLIN CHEM, V17, P111
[6] Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
Haffner, SM
Lehto, S
Rönnemaa, T
Pyörälä, K
Laakso, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) : 229 - 234
[7] Anion-exchange high-performance liquid chromatographic assay of plasma lipoproteins
Haginaka, J
Yamaguchi, Y
Kunitomo, M
[J]. ANALYTICAL BIOCHEMISTRY, 1995, 232 (02) : 163 - 171
[8] DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM
HAVEL, RJ
EDER, HA
BRAGDON, JH
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1955, 34 (09) : 1345 - 1353
[9] Pathophysiology of Diabetic Dyslipidemia
Hirano, Tsutomu
[J]. JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (09) : 771 - 782
[10] Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent
Hirowatari, Y
Yoshida, H
Kurosawa, H
Doumitu, K
Tada, N
[J]. JOURNAL OF LIPID RESEARCH, 2003, 44 (07) : 1404 - 1412

← 1 2 3 4 5 →